| Popis: |
Lingling Liu,1 Jin Wang,1 Huan Zhang,1 Mengli Chen,2 Yun Cai1 1Center of Medicine Clinical Research, Department of Pharmacy, Medical Supplies Center, PLA General Hospital, Beijing, People’s Republic of China; 2Department of Pharmacy, Medical Supplies Center, PLA General Hospital, Beijing, People’s Republic of ChinaCorrespondence: Yun CaiCenter of Medicine Clinical Research, Department of Pharmacy, Medical Supplies Center, PLA General Hospital, 28 Fu Xing Road, Beijing, 100853, People’s Republic of ChinaTel +86-10-6693-7166Email caicai_hh@126.comMengli ChenDepartment of Pharmacy, Medical Supplies Center, PLA General Hospital, 28 Fu Xing Road, Beijing, 100853, People’s Republic of ChinaTel +86-10-6693-9610Email helloLily301cn@126.comAbstract: As a heterogeneous and wide inflammation, osteoarticular infection (OAI) shows an increasing incidence in recent years. Staphylococcus aureus is the most important pathogen causing OAI. The antibiotic treatment will affect the outcomes of OAI patients, and the drug selection and dosage regimen highly rely on patients’ variability, pathogen susceptibility, and drug property like bone permeability. Model-informed precision dosing (MIPD) provides options to describe and quantify the pharmacokinetic (PK) variability of the OAI population using different models, such as the population pharmacokinetic (PPK) model and physiological-based pharmacokinetic (PB/PK) model. In the present review, we highlighted that the MIPD of antibiotics played a critical role in OAI and listed the dose regimen recommended by the model. Collectively, our current study provided a valuable reference for the treatment of patients and improved the safety and efficiency of drug use.Keywords: osteoarticular infection, antibiotic, PPK, PBPK, dose |
